Related Experiment Video

Updated: Sep 4, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.6K

Oncolytic immunotherapy: multiple mechanisms of oncolytic peptides to confer anticancer immunity

Tianyu Tang1,2,3,4,5, Xing Huang6,2,3,4,5, Gang Zhang1,2,3,4,5

  • 1Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China.

Journal for Immunotherapy of Cancer
|July 19, 2022
PubMed

Insights

Oncolytic peptides remodel the tumor microenvironment and boost anticancer immunity. LTX-315, an oncolytic peptide, enhances cancer immunotherapy by inhibiting PD-L1 expression, targeting the PD-1/PD-L1 axis.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Oncolytic peptides are potent agents for remodeling the tumor microenvironment and enhancing anticancer immunity.
  • They primarily induce immunogenic cell death, a key mechanism in potentiating anti-tumor responses.

Discussion:

  • LTX-315, a prominent oncolytic peptide, was shown to inhibit Programmed Death-Ligand 1 (PD-L1) expression.
  • This inhibition occurs through the ATP binding cassette subfamily B member 11 (ATP11B) pathway.
  • Targeting the PD-1/PD-L1 axis with LTX-315 enhances the efficacy of cancer immunotherapy.

Key Insights:

  • Oncolytic peptides offer a multifaceted approach to cancer treatment.
  • LTX-315 demonstrates a novel mechanism of action by modulating PD-L1 expression.
  • This peptide holds significant promise for improving cancer immunotherapy outcomes.

Outlook:

  • Further research into oncolytic peptides can uncover new therapeutic strategies.
  • Exploring the interplay between oncolytic peptides and immune checkpoints is crucial.
  • Optimizing oncolytic peptide-based therapies could revolutionize cancer treatment.
Keywords:
Drug Therapy, CombinationImmunotherapyOncolytic VirotherapyProgrammed Cell Death 1 ReceptorTumor Microenvironment

More Related Videos

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells08:02

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

2.6K
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.4K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
652
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
1.6K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
502
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
649
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
4.1K